Immunotherapy with Recombinant Human Interleukin 2 in Patients with Hematological Malignancies after Bone Marrow or Peripheral Blood Stem Cell Transplantation
作者： Frydecka I , Ciszak L , Kosmaczewska A , Boćko D , Kaczmarek P
DOI:
关键词:
摘要: A bstract. High-dose chemotherapy in conjunction with bone marrow transplantation (BMT) or peripheral blood stem cell (PBSCT) is increasingly being used for treatment of patients hematological malignancies. Residual tumor cells, resistant to high-dose chemoradiotherapy, are responsible reccurence the d isease. Interleukin 2 (IL-2), a pleiotropic cytokine which plays central role immune response, has been i ntroduced several clinical trials malignancies after B MT PBSCT increase immunocompetence these and eradicate residual malignant cells. At present there no general agreement on optimum dosage route administration also gave conflicting results. Establishment schedules methods should enable b etter assessment t he place IL-2 patients.
pan.wroc.pl 参考文章(24)
Collis C, Cunningham Jm, Gottlieb Dj, Smith Op, Gandhi L, Hamon, Prentice Hg, Macdonald Id, Gilmore M, Immunotherapy with interleukin 2 after ABMT in AML Bone Marrow Transplantation. ,vol. 11, pp. 399- 401 ,(1993)
LG Lum, The kinetics of immune reconstitution after human marrow transplantation. Blood. ,vol. 69, pp. 369- 380 ,(1987) , 10.1182/BLOOD.V69.2.369.369
RJ Soiffer, C Murray, K Cochran, C Cameron, E Wang, PW Schow, JF Daley, J Ritz, Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation Blood. ,vol. 79, pp. 517- 526 ,(1992) , 10.1182/BLOOD.V79.2.517.517
A Bacigalupo, MT Van Lint, D Occhini, F Gualandi, T Lamparelli, G Sogno, E Tedone, F Frassoni, J Tong, AM Marmont, Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood. ,vol. 77, pp. 1423- 1428 ,(1991) , 10.1182/BLOOD.V77.7.1423.1423
R B Herberman, E Lotzová, C A Savary, Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. Journal of Immunology. ,vol. 138, pp. 2718- 2727 ,(1987)
Harry W. Findley, Aly Aboel Mageed, Sherif A. Nasr, Abdelsalam H. Ragab, Recombinant lnterleukin-2 activates peripheral blood lymphocytes from children with acute leukemia to kill autologous leukemic cells Cancer. ,vol. 62, pp. 1928- 1931 ,(1988) , 10.1002/1097-0142(19881101)62:9<1928::AID-CNCR2820620910>3.0.CO;2-X
A. Lange, B. Jazwiec, B. Tomaszewska-Toporska, J. Topotski, Recovery of Natural Cytotoxicity After Bone Marrow Transplantation Immunological Investigations. ,vol. 20, pp. 207- 213 ,(1991) , 10.3109/08820139109050789
Helen E. Heslop, Andrew S. Duncombe, Joyce E. Reittie, Concha Bello-Fernandez, David J. Gottlieb, H. Grant Prentice, Atul B. Mehta, A. Victor Hoffbrand, Malcolm K. Brenner, Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. British Journal of Haematology. ,vol. 77, pp. 237- 244 ,(1991) , 10.1111/J.1365-2141.1991.TB07983.X
E Roldán, A García-Avello, J Odriozola, J López-Jiménez, J Pérez-Oteyza, A Muñoz, C Parra, L Villalón, P Ramos, M Maldonado, J García-Laraña, E Otheo, Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study. Bone Marrow Transplantation. ,vol. 19, pp. 429- 434 ,(1997) , 10.1038/SJ.BMT.1700693
A. Lange, H.-D. Flad, M. Ernst, A. Jacak, B. Jaźwiec, W. Scholz, A.J. Ulmer, Interleukin 2 induces appearance of LGL/Leu11+/K562 lytic cells in Leu11- low density peripheral blood mononuclear cell population. Immunology Letters. ,vol. 15, pp. 1- 7 ,(1987) , 10.1016/0165-2478(87)90068-X